The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models
Abstract
The cytochromes P450 (CYP s) constitute a superfamily of hemoprotein enzymes that are responsible for the biotransformation of numerous xenobiotics, including therapeutic agents. Studies of the biochemical and enzymatic properties of these enzymes and their molecular genetics and regulation of gene expression and activity have greatly enhanced our understanding of several aspects of clinical pharmacology such as pharmacokinetic variability, drug toxicity, and drug interactions. This review evaluates the major human hepatic drug‐metabolizing CYP enzymes and their clinically relevant substrates, inhibitors, and inducers. Also discussed are the molecular bases and clinical implications of genetic polymorphisms that affect the CYPs. Much of the information on the specificity of substrates and inhibitors of the CYP enzymes is derived from in vitro studies using human liver microsomes and heterologously expressed CYP enzymes. These methods are discussed, and guidelines are provided for designing enzyme kinetic and reaction phenotyping studies using multiple approaches. The strengths, weaknesses, and discrepancies among the different approaches are considered using representative examples. The mathematical models used in predicting the pharmacokinetic clearance of a drug from in vitro estimates of intrinsic clearance and the principles of quantitative in vitro‐in vivo scaling of metabolic drug interactions are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 13×
“CYP2A6 may participate in procarcinogen activation but has a relatively minor role in drug biotransformation and accounts for only approximately 4% of total immunoquantified human hepatic CYP.7 CYP2A6 is a coumarin 7-hydroxylase, partici- pates in nicotine metabolism, and contributes to the reductive metabolism of the…”
BackgroundInfluentialYamaoka, K., Nakagawa, T., & Uno, T. (1978) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01117450 · Cited by 2,057
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Fitting curves to data using nonlinear regression: a practical and nonmathematical review
Motulsky, H. J., & Ransnas, L. A. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.5.3315805 · Cited by 1,327
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 3×
“The estimation of intrinsic clearance assumes that this parameter serves as a direct proportionality constant relating drug concentration to metabolic rate.(51) This assumption is not strictly valid for Hill kinetics (Equation 5), for which the v/S ratio increases with substrate concentration, reaches a maximum at the…”
BackgroundMethodCytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., & Tracy, T. S. (1998) · Biochemistry · doi:10.1021/bi9715627 · Cited by 511
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Self-citationPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Nicotine metabolism defect reduces smoking
Pianezza, M. L., Sellers, E. M., & Tyndale, R. F. (1998) · Nature · doi:10.1038/31623 · Cited by 432
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
Rahman, A., Korzekwa, K., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994) · PubMed · Cited by 430
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Obach, R. S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39043-3 · Cited by 397
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Self-citationNomenclature for human CYP2D6 alleles
Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Houston, J. B., & Kenworthy, K. E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15358-5 · Cited by 389
[10] Mechanism-based enzyme inactivators
Silverman, R. B. (1995) · Methods in Enzymology · doi:10.1016/0076-6879(95)49038-8 · Cited by 384
Cooperativity in Oxidations Catalyzed by Cytochrome P450 3A4
Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., & Guengerich, F. P. (1997) · Biochemistry · doi:10.1021/bi962359z · Cited by 383
Leung, D. M., Kurt-Jones, E., Newburger, J., Cotran, R., Burns, J., & Pober, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91910-7 · Cited by 381
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
(1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00268-8 · Cited by 369
Bourrié, M., Meunier, V, Berger, Y., & Fabre, G. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12826-7 · Cited by 363
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Chauret, N., Gauthier, A., & Nicoll‐Griffith, D. A. (1998) · PubMed · Cited by 357
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V., & Korzekwa, K. R. (1994) · Biochemistry · doi:10.1021/bi00187a009 · Cited by 351
Characterization of Human Small Intestinal Cytochromes P-450
Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., & Kaminsky, L. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15229-4 · Cited by 343
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Eagling, V. A., Tjia, J. F., & Back, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00679.x · Cited by 333
Roy, P., Yu, L. J., Crespi, C. L., & Waxman, D. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15302-0 · Cited by 320
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V., & Miners, J. O. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38136-x · Cited by 316
Busby, W. F., Ackermann, J. M., & Crespi, C. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15284-1 · Cited by 307
Ludden, T. M., Beal, S. L., & Sheiner, L. B. (1994) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353864 · Cited by 306
Lang, D., Yeung, C., Peter, R., Ibarra, C., Gasser, R., Itagaki, K., Philpot, R., & Rettie, A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00218-4 · Cited by 303
Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., & Chenery, R. J. (1995) · Xenobiotica · doi:10.3109/00498259509061850 · Cited by 298
Fernández‐Salguero, P. M., Hoffman, S. M. G., Cholerton, S., Mohrenweiser, H. W., Raunio, H., Rautio, A., Pelkonen, O., Huang, J. D., Evans, W. E., & Idle, J. R. (1995) · PubMed · Cited by 293
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Drug metabolism by Escherichia coli expressing human cytochromes P450
Parikh, A., Gillam, E. M. J., & Guengerich, F. P. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-784 · Cited by 285
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., & Sugiyama, Y. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.
Sesardic, D., Boobis, A., Murray, B., Murray, S., Segura, J., de la Torre, R., & Davies, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03686.x · Cited by 278
Cytochromes P450. Metabolic and Toxicological Aspects
Shuster, L. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00025 · Cited by 271
Forty Years of Cytochrome P450
Omura, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1887 · Cited by 270
Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R., & Branch, R. A. (1984) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1984.256 · Cited by 263
Huang, Z., Roy, P., & Waxman, D. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00410-4 · Cited by 263
TSUNODA, S., VELEZ, R., VONMOLTKE, L., & GREENBLATT, D. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70009-3 · Cited by 257
Self-citationBiochemical toxicology: A practical approach
Marzin, D. (1988) · Biochimie · doi:10.1016/0300-9084(88)90081-8 · Cited by 255
Effects of Freezing, Thawing, and Storing Human Liver Microsomes on Cytochrome P450 Activity
Pearce, R. E., McIntyre, C. J., Madan, A., Sanzgiri, U., Draper, A. J., Bullock, P. L., Cook, D. C., Burton, L. A., Latham, J., Nevins, C., et al. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0294 · Cited by 253
Chang, T. K. H., Gonzalez, F. J., & Waxman, D. J. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1259 · Cited by 251
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir
von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04398.x · Cited by 248
Self-citationGibbs, M. A., Thummel, K. E., Shen, D. D., & Kunze, K. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15274-9 · Cited by 245
Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. H., & Waxman, D. J. (1997) · PubMed · Cited by 245
Biochemical toxicology : a practical approach
Snell, K., & Mullock, B. M. (1987) · IRL Press eBooks · Cited by 240
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J., & Tsutsui, M. (1996) · Xenobiotica · doi:10.3109/00498259609046742 · Cited by 233
Forrester, L. M., Henderson, C. J., Glancey, M. J., Back, D. J., Park, B. K., Ball, S. E., Kitteringham, N. R., McLaren, A. W., Miles, J. S., Skett, P., et al. (1992) · Biochemical Journal · doi:10.1042/bj2810359 · Cited by 233
Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
Hamman, M. A., Thompson, G. A., & Hall, S. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00143-3 · Cited by 230
Harlow, G. R., & Halpert, J. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6636 · Cited by 228
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene
Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200103000-00002 · Cited by 226
von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., & Shader, R. I. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12284-2 · Cited by 225
Self-citationHickman, D., Wang, J. P., Wang, Y., & Unadkat, J. D. (1998) · PubMed · Cited by 222
Cytochromes P450: Metabolic and Toxicological Aspects
Ioannides, C. (1996) · Medical Entomology and Zoology · Cited by 220
Elucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4
Hosea, N. A., Miller, G. P., & Guengerich, F. P. (2000) · Biochemistry · doi:10.1021/bi992765t · Cited by 219
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04251.x · Cited by 218
Self-citationRing, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., & Wrighton, S. A. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12326-4 · Cited by 214
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko, J. W., Sukhova, N., Thacker, D. L., Chen, P., & Flockhart, D. A. (1997) · PubMed · Cited by 209
Court, M. H., Duan, S. X., Hesse, L. M., Venkatakrishnan, K., & Greenblatt, D. J. (2001) · Anesthesiology · doi:10.1097/00000542-200101000-00021 · Cited by 207
Self-citationcDNA Cloning and Initial Characterization of CYP3A43, a Novel Human Cytochrome P450
Domanski, T. L., Finta, C., Halpert, J. R., & Zaphiropoulos, P. G. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12850-7 · Cited by 205
Venkatakrishnan, K., von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13680-x · Cited by 200
Self-citationBajpai, M., Roskos, L. K., Shen, D. D., & Levy, R. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08481-8 · Cited by 199
In Vitro Approaches to Predicting Drug Interactions In Vivo
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00239-6 · Cited by 197
Self-citationSULPHAPHENAZOLE-INDUCED HYPOGLYCÆMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS
Korsgaard Christensen, L., Mølholm Hansen, J., & Kristensen, M. (1963) · The Lancet · doi:10.1016/s0140-6736(63)90847-x · Cited by 195
Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes
Draper, A. J., Madan, A., & Parkinson, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9964 · Cited by 191
Easterbrook, J. D., Lu, C., Sakai, Y., & Li, A. P. (2001) · PubMed · Cited by 190
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
Lin, Y., Lü, P., Tang, C., Mei, Q., Sandig, G., Rodrigues, A. D., Rushmore, T. H., & Shou, M. (2001) · PubMed · Cited by 182
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
Sellers, E. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.107651 · Cited by 179
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., & Wrighton, S. A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37719-5 · Cited by 178
von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199504000-00008 · Cited by 176
Self-citationFogelman, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00113-4 · Cited by 175
Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 175
Self-citationYamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., & Shimada, T. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 172
On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
Lewis, D. F. V. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00335-x · Cited by 168
Gugler, R., & Jensen, J. C. (1985) · PubMed · Cited by 164
von Moltke, L., Greenblatt, D., Cotreau‐Bibbo, M., Harmatz, J., & Shader, R. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04317.x · Cited by 161
Self-citationCrespi, C. L., & Miller, V. P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00028-5 · Cited by 161
Omeprazole inhibits oxidative drug metabolism
Gugler, R., & Jensen, J. C. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90638-9 · Cited by 158
Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
Crespi, C. L. (1995) · Advances in Drug Research · doi:10.1016/s0065-2490(05)80006-1 · Cited by 157
Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38622-2 · Cited by 156
Self-citationShou, M., Qin, M. E. I., ETTORE, J. M. W., Dai, R., Baillie, T. A., & Rushmore, T. H. (1999) · Biochemical Journal · doi:10.1042/bj3400845 · Cited by 155
PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS
Iwatsubo, T., Hirota, N., Ooie, T., SUZUKI, H., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199605)17:4<273::aid-bdd961>3.0.co;2-r · Cited by 154
ODANI, A., Hashimoto, Y., OTSUKI, Y., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90031-x · Cited by 154
Nonspecific binding of drugs to human liver microsomes
McLure, J. A., Miners, J. O., & Birkett, D. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00193.x · Cited by 152
Lasker, J. M., Wester, M. R., Aramsombatdee, E., & Raucy, J. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0615 · Cited by 150
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Duan, S. X., Grassi, J. M., Venkatakrishnan, K., Harmatz, J. S., & Shader, R. I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00953.x · Cited by 149
Self-citationInduction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang, L., Wring, S. A., Woolley, J. L., Brouwer, K. R., Serabjit‐Singh, C. J., & Polli, J. W. (2001) · PubMed · Cited by 142
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs, L. L., Peter, R. M., Thompson, S. J., Rettie, A. E., & Trager, W. F. (1997) · PubMed · Cited by 140
Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.
Stevens, J. C., & Wrighton, S. A. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38409-0 · Cited by 138
Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P., & Shimada, T. (1997) · Pharmacogenetics · doi:10.1097/00008571-199704000-00003 · Cited by 135
Obach, R. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08404-1 · Cited by 134
McGinnity, D. F., Parker, A. J., Soars, M. G., & Riley, R. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15081-7 · Cited by 132
Site-directed mutation studies of human liver cytochrome P -450 isoenzymes in the CYP2C subfamily
Veronese, M., Doecke, C. J., Mackenzie, P. I., McManus, M. E., Miners, J. O., Rees, D. L. P., Gasser, R. B., Meyer, U., & Birkett, D. (1993) · Biochemical Journal · doi:10.1042/bj2890533 · Cited by 131
Onof, S., Hatanaka, T., Miyazawa, S., Tsutsui, M., Aoyama, T., Gonzalez, F. J., & Satoh, T. (1996) · Xenobiotica · doi:10.3109/00498259609050260 · Cited by 130
Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions
Crespi, C. L., & Penman, B. W. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60205-7 · Cited by 129
Alprazolam-ritonavir interaction: Implications for product labeling
Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Durol, A. L., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.105757 · Cited by 128
Self-citationInhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Giancarlo, G. M., Duan, S. X., Daily, J. P., Harmatz, J. S., & Shader, R. I. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122009728 · Cited by 127
Self-citationIn vitro assessment of human cytochrome P450
Clarke, S. E. (1998) · Xenobiotica · doi:10.1080/004982598238877 · Cited by 127
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
Carlile, D. J., Hakooz, N., Bayliss, M. K., & Houston, J. B. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00935.x · Cited by 126
Greenblatt, D. J., Wright, C. E., Moltke, L. L., Harmatz, J. S., Ehrenberg, B. L., Harrel, L., Corbett, K., Counihan, M., Tobias, S., & Shader, R. I. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90172-2 · Cited by 126
Self-citationStürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
Self-citationMancy, A., Dijols, S., Poli, S. M., Guengerich, F. P., & Mansuy, D. (1996) · Biochemistry · doi:10.1021/bi961950t · Cited by 123
Moltke, L. L., Greenblatt, D. J., Schmider, J., Harmatz, J. S., & Shader, R. I. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00007 · Cited by 121
Self-citationHarvey, A. T., & Preskorn, S. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00002 · Cited by 116
(2013) · Methods in molecular biology · doi:10.1007/978-1-62703-321-3 · Cited by 115
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., & Shader, R. I. (1996) · Psychopharmacology · doi:10.1007/s002130050149 · Cited by 115
Self-citationIn Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb04735.x · Cited by 115
Self-citationBack, D., Tjia, J. F., Karbwang, J., & Colbert, J. E. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03359.x · Cited by 112
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29543-4 · Cited by 112
Self-citationMonospecific Antipeptide Antibody to Cytochrome P-450 2B6
Stresser, D. M., & Kupfer, D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15215-4 · Cited by 111
Tran, A., Rey, E., Pons, G., Rousseau, M., d’Athis, P., Olivé, G., MATHER, G. G., Bishop, F. E., Wurden, C. J., Labroo, R. B., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90044-8 · Cited by 110
Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06914.x · Cited by 108
Self-citationSchmider, J., Greenblatt, D. J., Moltke, L. L., Karsov, D., & Shader, R. I. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00601.x · Cited by 104
Self-citationDifferential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Durol, A. L. B., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200006010-00007 · Cited by 103
Self-citationShaw, P. M., Hosea, N. A., Thompson, D. V., Lenius, J. M., & Guengerich, F. P. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0378 · Cited by 102
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008173 · Cited by 102
Self-citationMoltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Duan, S. X., Fogelman, S. M., Harmatz, J. S., & Shader, R. I. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00353-9 · Cited by 100
Self-citationShimada, T., Tsumura, F., & Yamazaki, H. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14929-x · Cited by 98
Koyama, E., Chiba, K., Tani, M., & Ishizaki, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36731-x · Cited by 95
Kerr, B. M., Rettie, A. E., Eddy, A. C., Loiseau, P., Guyot, M., Wilensky, A. J., & Levy, R. H. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.110 · Cited by 92
Paine, M. F., Schmiedlin‐Ren, P., & Watkins, P. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14911-2 · Cited by 91
Witherow, L. E., & Houston, J. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34868-2 · Cited by 90
Schmider, J., Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., & Shader, R. I. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12105-8 · Cited by 89
Self-citationInduction of P-glycoprotein expression by HIV protease inhibitors in cell culture
Perloff, M. D., Moltke, L. L., Fahey, J. M., Daily, J. P., & Greenblatt, D. J. (2000) · AIDS · doi:10.1097/00002030-200006160-00034 · Cited by 88
Self-citationvon Moltke, L. L., Durol, A. L. B., Duan, S. X., & Greenblatt, D. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000125 · Cited by 85
Self-citationDrug Interactions and the Cytochrome P450 System
Flockhart, D. A. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00008 · Cited by 84
Shibata, Y., Takahashi, H., & Ishii, Y. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)11800-4 · Cited by 84
Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine.
Cashman, J. R., PARK, S. B., Yang, Z., Washington, C. B., Gomez, D. Y., Giacomini, K. M., & Brett, C. M. A. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07460-4 · Cited by 83
Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo, Z., Raeissi, S., White, R. B., & Stevens, J. C. (1997) · PubMed · Cited by 82
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole*
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Mertzanis, P., Graf, J. A., Durol, A. L. B., Counihan, M., Roth‐Schechter, B. F., & Shader, R. I. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90057-1 · Cited by 81
Self-citationHemeryck, A., Vriendt, C. D., & Belpaire, F. M. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050580 · Cited by 81
Microsomal Binding of Amitriptyline: Effect on Estimation of Enzyme Kinetic Parameters In Vitro
Venkatakrishnan, K., Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39241-9 · Cited by 79
Self-citationVenkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980255z · Cited by 77
Self-citationN-oxygenation of clozapine by flavin-containing monooxygenase.
Tugnait, M., Hawes, E. M., McKay, G., Rettie, A. E., Haining, R. L., & Midha, K. K. (1997) · PubMed · Cited by 75
Ieiri, I., Tainaka, H., Morita, T., et al. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200006000-00001 · Cited by 72
CYP2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes
Wester, M. R., Lasker, J. M., Johnson, E. F., & Raucy, J. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15373-1 · Cited by 71
DRUG‐MEDIATED INACTIVATION OF CYTOCHROME P450
Murray, M. T. (1997) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1997.tb01228.x · Cited by 71
Harvey, A. T., & Preskorn, S. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00002 · Cited by 66
Extensive Impairment of Triazolam and Alprazolam Clearance by Short-Term Low-Dose Ritonavir
Greenblatt, D. J., Moltke, L. L., Daily, J. P., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00001 · Cited by 65
Self-citationLudwig, E., Schmid, J., Beschke, K., & Thomas, E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34860-8 · Cited by 61
Schrag, M. L., & Wienkers, L. C. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0667-6_56 · Cited by 61
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970435t · Cited by 61
Self-citationGreenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04252.x · Cited by 60
Self-citationYasumori, T., Li, Q., Yamazoe, Y., Tsuzuki, T., Kato, R., & Ueda, M. (1994) · Pharmacogenetics · doi:10.1097/00008571-199412000-00005 · Cited by 59
Gibbs, M. A., Kunze, K. L., Howald, W. N., & Thummel, K. E. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15255-5 · Cited by 59
The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl
Palkama, V. J., Neuvonen, P. J., & Olkkola, K. T. (1998) · British Journal of Anaesthesia · doi:10.1093/bja/81.4.598 · Cited by 59
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.
Ko, J.-W., Desta, Z., & Flockhart, D. A. (1998) · PubMed · Cited by 58
Zalma, A., Moltke, L. L., Granda, B. W., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00176-6 · Cited by 57
Self-citationStörmer, E., Moltke, L. L., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38970-0 · Cited by 53
Self-citationSchmider, J., Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.35717.x · Cited by 51
Self-citationEffect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine
Isohanni, M. H., Neuvonen, P. J., Palkama, V. J., & Olkkola, K. T. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050513 · Cited by 49
In vitro metabolic interaction studies: Experience of the Food and Drug Administration
Yuan, R., PARMELEE, T., Balian, J. D., Uppoor, R. S., Ajayi, F., Burnett, A. L. “., Lesko, L. L., & Marroum, P. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70048-2 · Cited by 48
Comparison of (S)‐mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms
Coller, Somogyi, & Bochner (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00005.x · Cited by 46
The Role of CYP2C19 in the Metabolism of (+/–) Bufuralol, the Prototypic Substrate of CYP2D6
Mankowski, D. C. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15021-0 · Cited by 45
Schmider, J., Moltke, L. L., Shader, R. I., Harmatz, J. S., & Greenblatt, D. J. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101935 · Cited by 43
Self-citationRodrigues, A. D., & Wong, S. L. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60202-1 · Cited by 40
Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes
Bhamre, S., Bhagwat, S. V., Shankar, S. K., Boyd, M. R., & Ravindranath, V. (1995) · Brain Research · doi:10.1016/0006-8993(94)01135-5 · Cited by 39
Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4
Coller, J. K., Somogyi, A. A., & Bochner, F. (1999) · Xenobiotica · doi:10.1080/004982599238056 · Cited by 38
Schrag, M. L., & Wienkers, L. C. (2001) · PubMed · Cited by 37
Gass, R. J., Gal, J., Fogle, P. W., Detmar-Hanna, D., & Gerber, J. G. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050545 · Cited by 35
Richardson, T. H., Griffin, K. J., Jung, F., Raucy, J. L., & Johnson, E. F. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9817 · Cited by 35
The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1996) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00312.x · Cited by 34
Bhamre, S., Bhagwat, S. V., Shankar, S. K., Williams, D. E., & Ravindranath, V. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39557-1 · Cited by 33
Miles, J. S., McLaren, A. W., & Wolf, C. R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.20.8241 · Cited by 28
Cytochrome P450 Reconstitution Systems
Shimada, T., & Yamazaki, H. (2003) · Humana Press eBooks · doi:10.1385/0-89603-519-0:85 · Cited by 26
Activation of phenacetinO-deethylase activity byα-naphthoflavone in human liver microsomes
Nakajima, M., Kobayashi, K., Oshima, K., Shimada, N., Tokudome, S., Chiba, K., & Yokoi, T. (1999) · Xenobiotica · doi:10.1080/004982599238137 · Cited by 25
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1998) · Pharmacy and Pharmacology Communications · doi:10.1111/j.2042-7158.1998.tb00727.x · Cited by 22
Self-citationVenkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14965-3 · Cited by 18
Self-citationPresystemic Extraction: Mechanisms and Consequences
Greenblatt, D. J. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb04719.x · Cited by 17
Self-citation
Cited by
Interactions of Herbs with Cytochrome P450
Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., & Paxton, J. W. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120018248 · Cited by 397
Varma, M. V. S., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 331
Saad, A. H., DePestel, D. D., & Carver, P. L. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12.1730 · Cited by 295
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Self-citationZhang, D., Chando, T. J., Everett, D. W., Patten, C. J., Dehal, S. S., & Humphreys, W. G. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005447 · Cited by 286
Metadata
- Authors
- Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2001-11
- Volume
- 41
- Issue
- 11
- Pages
- 1149-1179
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2066312456
- Cited by
- 308
- References
- 195
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.